OrientBio Targets Female Pattern Hair Loss Market... Accelerates Development of Next-Generation Hair Growth Drug OND-1

OrientBio is targeting the female pattern hair loss treatment market.

According to OrientBio on July 9, its new drug candidate for hair growth, OND-1, is being developed with a mechanism that differentiates it from existing hair loss treatments. Rather than relying on male hormone regulation, OND-1 is based on a non-hormonal mechanism that acts directly on the growth signaling pathways of hair follicles. This candidate is regarded as having the potential to broaden its application to female pattern hair loss, while reducing the risk of hormone-related side effects.

The company has confirmed the excellent hair growth efficacy and safety of OND-1 through human hair follicle culture tests and animal experiments. Based on the results of preclinical studies, OrientBio plans to secure a competitive edge that sets it apart from existing treatments.

To enhance drug efficacy duration and therapeutic efficiency, OrientBio has also secured a sustained-release drug delivery technology using the biodegradable polymer PLGA. This technology is designed to deliver the drug to the dermal layer surrounding hair follicles, allowing the effect to be sustained locally. The technology has already been patented in Korea and Japan, and the company is seeking patent protection in other major markets such as the United States, Europe, and China. OrientBio’s goal is to develop OND-1 into a platform-type new drug that can be used for both male and female hair loss treatment in the future.

An OrientBio official stated, "OND-1 is a promising candidate with strong scalability that can expand its range of application not only to male pattern hair loss, but also to female pattern hair loss, where treatment alternatives are limited. We will continue to strengthen our new drug development, formulation technology, and global patent strategy to secure global competitiveness."

This content was produced with the assistance of AI translation services.